Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2000 4
2002 4
2003 1
2004 4
2005 4
2006 6
2007 9
2008 8
2009 10
2010 6
2011 8
2012 10
2013 10
2014 7
2015 14
2016 7
2017 12
2018 15
2019 14
2020 10
2021 16
2022 10
2023 17
2024 16
2025 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

204 results

Results by year

Filters applied: . Clear all
Page 1
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Verstovsek S, et al. Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0. Lancet. 2023. PMID: 36709073 Clinical Trial.
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators. Levis MJ, et al. J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12. J Clin Oncol. 2024. PMID: 38471061 Free PMC article. Clinical Trial.
Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study.
Bassan R, Chiaretti S, Della Starza I, Santoro A, Spinelli O, Tosi M, Elia L, Cardinali D, De Propris MS, Piccini M, Lussana F, Annunziata M, Chiusolo P, Zappasodi P, Borlenghi E, Leoncin M, Califano C, Bocchia M, Di Raimondo F, Grimaldi F, Tiribelli M, Candoni A, Lico A, Audisio E, Lunghi M, Mianulli AM, Di Trani M, Arena V, Messina M, Piciocchi A, Fazi P, Rambaldi A, Foà R. Bassan R, et al. Among authors: tiribelli m. Blood. 2025 May 22;145(21):2447-2459. doi: 10.1182/blood.2024027500. Blood. 2025. PMID: 40009490 Clinical Trial.
Checkpoint Inhibitors in Acute Myeloid Leukemia.
Damiani D, Tiribelli M. Damiani D, et al. Among authors: tiribelli m. Biomedicines. 2023 Jun 15;11(6):1724. doi: 10.3390/biomedicines11061724. Biomedicines. 2023. PMID: 37371818 Free PMC article. Review.
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.
Palandri F, Elli EM, Morsia E, Benevolo G, Tiribelli M, Beggiato E, Bonifacio M, Farina M, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Iurlo A, Isidori A, Bosi C, Guglielmana V, Venturi M, Dedola A, Loffredo M, Fontana G, Duminuco A, Moioli A, Tosoni L, Scalzulli E, Cattaneo D, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Vianelli N, Cavo M, Palumbo GA, Branzanti F, Breccia M. Palandri F, et al. Among authors: tiribelli m. Cancer. 2024 Dec 15;130(24):4257-4266. doi: 10.1002/cncr.35489. Epub 2024 Jul 30. Cancer. 2024. PMID: 39078647 Free PMC article.
Editorial: Advances in the treatment of chronic myeloid leukemia.
Eşkazan AE, Kok CH, Yeung D, Dalal J, Tiribelli M. Eşkazan AE, et al. Among authors: tiribelli m. Front Oncol. 2023 Mar 9;13:1166588. doi: 10.3389/fonc.2023.1166588. eCollection 2023. Front Oncol. 2023. PMID: 36969003 Free PMC article. No abstract available.
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators. Saglio G, et al. N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525993 Free article. Clinical Trial.
The triple A (AAA) model globally recapitulates adverse outcomes in essential thrombocythemia.
Tosoni L, Morelli GL, Tomadini G, Lazzarotto D, Filì C, Simeone E, Zannier ME, Callegari C, Fanin M, Battaglia G, Bergnach M, Damiani D, Fanin R, Tiribelli M. Tosoni L, et al. Among authors: tiribelli m. Blood Cancer J. 2024 Oct 1;14(1):169. doi: 10.1038/s41408-024-01151-2. Blood Cancer J. 2024. PMID: 39353890 Free PMC article. No abstract available.
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI).
Breccia M, Palandri F, Martelli M, Mendicino F, Malato A, Palumbo GA, Sibilla S, Di Renzo N, Abruzzese E, Siragusa S, Crugnola M, Selleri C, Pane F, Sportoletti P, Martino B, Impera S, Ricco A, Langella M, Ditonno P, Carli G, Itri F, Liberati AM, Urbano T, Tafuri A, Polizzi V, Pastore D, Morsia E, Benevolo G, Micucci G, Farina G, Bonifacio M, Elli EM, Gardellini A, De Stefano V, Caocci G, Falcone AP, Vallisa D, Brociner M, Tiribelli M, Binotto G, Pocali B, Cavazzini F, Tomassetti S, Lunghi F, Di Ianni M, Allegra A, Anaclerio B, Mazzotta S, Orofino N, Gherlinzoni F, Castiglioni C, Landoni M, Valsecchi D, Magnoli M, Guglielmelli P, Passamonti F. Breccia M, et al. Among authors: tiribelli m. Cancer. 2025 Apr 1;131(7):e35801. doi: 10.1002/cncr.35801. Cancer. 2025. PMID: 40111826 Free PMC article.
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study.
Palandri F, Breccia M, Morsia E, Elli EM, Benevolo G, Tiribelli M, Beggiato E, Farina M, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Isidori A, Dedola A, Scalzulli E, Moioli A, Cavalca F, Caserta S, Duminuco A, Martino B, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Bonifacio M, Palumbo GA, Branzanti F, Iurlo A, Abruzzese E. Palandri F, et al. Among authors: tiribelli m. Leuk Res. 2025 Jul;154:107719. doi: 10.1016/j.leukres.2025.107719. Epub 2025 May 27. Leuk Res. 2025. PMID: 40460507 No abstract available.
204 results